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INTRODUCTION 
               Central nervous system infections are the most important health issue 
due to high mortality and morbidity. This type of infections can be produced by 
bacteria, virus, fungi, and parasites. Symptoms of central nervous system 
infection produces discrete clinical syndrome includes acute bacterial 
meningitis, viral meningitis, encephalitis and brain abscess. Direct injury to the 
brain tissue produces inflammation of the brain tissue as well as meninges 
together called as meningoencehalitis. 
Meningoencephalitis  
              Meningoencephalitis is a clinical condition where we can observe the 
encephalitis, infection or inflammation of brain tissue and meningitis, infection 
or inflammation of meninges.1  
  Acute encephalitis syndrome 
     In this study the word acute encephalitis syndrome is synonymously 
used for meningoencephalitis1. . Above the all causes of meningoencephalitis, 
bacterial meningitis is the most common suppurative infection of nervous 
system. Viral causes are coming next to the bacterial cause. among the viral 
meningoencephalitis Japanese encephalitis has attained the main place may be 
due to high mortality and morbidity . 
 Incidence of the menigoencephalitis is about 2 cases per 1lakh 
populations.  Among viral menigoencephalitis infections, arthropod borne, 
arboviral infections are having incidence of about 1case per 1lakh population1. 
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Japanese encephalitis                                           
 Japanese encephalitis   is an acute viral infection caused by mosquito 
borne Japanese encephalitis virus. JE virus is a virus from flaviviridae. 
Domestic pigs and wild birds are reservoirs of the virus, the most important 
vectors of the disease are the culex mosquitos .Japanese encephalitis virus 
causes most serious clinical disease among the flavivirus group. 
          Infection with Japanese encephalitis virus may cause febrile illness, 
meningitis, or encephalitis and meningoencephalitis, clinically indistinguishable 
from other cause of acute encephalitis syndrome Approximately 3 billion 
people live in endemic regions. Incidence of 55,000 human cases and 11,000 
deaths have been noted annually in world wide3. Roughly 26% patients of 
encephalitis die due to the infection of JEV.1, 2 
       50% of the patients who are all the survivors will develop permanent 
neurological symptoms.  Mortality being high in this disease, identification of 
viral infection and early diagnosis in infection prone area has the crucial role in 
the management. In India, epidemics of JE were reported from many parts of 
the country, and it was considered a major health issue.  
        The first recognition of JE was based on serological surveys which were 
conducted in 1955, in Tamil Nadu .Totally 66 cases were reported between the 
period of 1956 and 1966 in Southern India. Successive surveys were carried out 
by that indicates approximately half of the population in South India has 
neutralizing antibodies to the virus. A major outbreak was recorded in 1973 in 
west Bengal resulting in a 42.6% fatality rate4. Consequently, the disease spread 
to other states, caused a series of outbreaks in various parts of the country. 
Cases were reported from 21 states and union territories in 1978. In Uttar 
Pradesh, the first major JE epidemic occurred in Gorakhpur in 1978, with 1,102 
cases and 297 deaths reported. In 2005 epidemic surpassed all previous reported 
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outbreaks in the country. In that year, Uttar Pradesh faced a demoralizing 
outbreak of JEV, mostly restricted to Gorakhpur, with 6,051 cases and 1,510 
deaths. Subsequently another outbreak occurred in 2006 where with 2,320 cases 
and 528 deaths. Likewise, JE cases in Uttar Pradesh were cramped 
predominantly to Gorakhpur during 2007, with 3,534cases and 756 deaths, and 
then onwards till 2007 there have been 103,874 reported cases in India, and 
33,729 deaths5. Roughly 597,657,000 people in India live in JE-endemic 
regions, and 1,600 to 4,500 cases are reported every year.4  
       A relative study exhibit the total number of cases and deaths in India from 
2005 to 2010 shows higher incidence of cases in Northern India than in Tamil 
nadu4; but the actual enormity of JE may be higher due to lack in reporting and 
expensive diagnostic methods.  
       In India, Serum and CSF samples, are taken for IgM by ELISA test, is 
widely used for the diagnosis of JE. The time of diagnosis with CSF sample is 
earlier (1-2days) compared to the serum (5-6days). The other diagnostic 
methods are PCR and Cell culture. IgM ELISA test is readily available and 
economical when compared to PCR and Cell culture. Hence I choose this study 
to compare the reliability of IgM ELISA and PCR along with cytological 
analysis of cerebrospinal fluid.                                        
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AIMS AND OBJECTIVES 
 
1. To   study the incidence of JE in patients admitted with 
meningoencephalitis. 
 
2. To study the cytological and chemical analysis of all CSF samples   in 
suspected meningoencephalitis patients admitted in Thanjavur Medical 
College hospital  
 
3. To study the serodiagnosis of JE by IgM capture ELISA in all CSF 
samples of patients admitted with suspected  meningoencephalitis   in  a 
tertiary care  hospital  Thanjavur . 
 
4. To study the molecular characterization of JE virus by polymerase chain 
reaction (RT-PCR) 
 
 
5. To study the comparison of IgM ELISA and polymerase chain reaction 
(RT-PCR) in association with cytological and bio chemical analysis of 
CSF. 
 
 
  
 
  
5 
 
 
REVIEW OF LITERATURE 
                         Meningitis is an acute purulent infection with in the 
subarachnoid space. This may be due to bacterial, viral, fungal, and parasites. 
This type of infections may lead to central nervous system inflammation. 
Subsequently it will produce fever, head ache, seizure, hemiparesis, neck 
rigidity, elevated intra cranial pressure, loss of consciousness and stroke. 
 Bacterial causes 
      1. Hemophilus influenza type b 
      2.Neisseria meningitides 
      3.Listeria monocytogen 
      4. Mycobacterium Tuberculosis 
     5. Leptospira 
 Viral causes 
1. Japanese  encephalitis virus 
2.  Herpes  simplex virus 
3.  Enterovirus 
Protozoal and fungus 
     1. Toxoplasma 
     2. Cryptococcus. 
 
 
  
6 
 
 
Epidemiological characters 
Bacterial causes are the commonest type of central nervous system 
infection, with a yearly incidence of 2 cases/1lakh populations5.  
The most frequently responsible organisms of bacterial meningitis are 
pneumococcus (-49%), Neisseria (-26%), group B streptococci(-16%), and 
Listeria (-12%). Haemophilus type b records for less than 10% of cases among 
bacterial meningitis. N. meningitidis is the most common   organism causing  
epidemics of meningitis  among 8 to 12 years of age group5. 
Causative organisms 
 Streptococcus pneumonia  
                Streptococcus pneumonia is the most common organism producing 
purulent infections in adults. There are number of conditions that increase the 
risk ofpneumococcal meningitis.  
The morbidity and mortality is high even in antimicrobial treatment. Rate 
of mortality is up to 20% in  untreated cases.5  
            The cases of meningitis have been declined due to Neisseria infection, 
due to regular and routine immunization programs. The vaccine contains 
serogroup A6.sero group B is not present in the vaccine .This is the reason for 
the present cases. 
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 Gram negative bacilli are one of the cause for bacterial meningitis among 
diabetics and immune compromised. 
  Streptococcus, agalactiae, which was previously responsible for 
meningitis in infants but now the cases in neonates have declined when 
compared to geriatric age group. 
 L. monocytogenes is a progressively more important cause of meningitis 
in pregnancy, neonatal period and individuals more than 60 years old and 
immune compromised of all ages. 
 H.influenzae type B meningitis in pediatric age group has decreased due 
to the introduction of   HIB vaccination. 
 Staphylococcus aureus and coagulase negative staphylococci (CONS) 
are the significant cause of meningitis after invasive surgeries. 
    Coagulase negative staphylococci ( Cons) ,the normal skin flora 
produces the meningitis in patients who are all underwent neurosurgical 
procedures. 
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Pathophysiology 
 Commonest bacteria that cause meningitis are S. pneumonia and 
Neisseria which forms colonization over the pharynx by attaching to the 
epithelial cells of nasopharynx7. Bacterial organisms are elated across epithelial 
cells in membrane bound vacuoles to the intravascular space. If the organisms 
escapes from the blood stream from phagocytosis, it can easily reach the 
intraventricular choroid plexus and get in to the CSF. Normally CSF contains 
some white blood cells and small amount of complement proteins and 
immunoglobulins. Phagocytosis ,the procedure of engulfment to destroy the 
bacteria is impaired by the fluid nature of CSF. Fluid nature of CSF 
contributing less in phagocytosis when compared to solid tissue 7. 
Clinical  features 
Meningitis can present as an acute illness that progress rapidly in a few 
hours or as a sub acute infection that progressively worsens over several days. 
The classical pictures of meningitis are temperature, vomiting, head ache and 
neck rigidity. A decreased level of consciousness occurs in more than 75% of 
patients8. Nausea, vomiting and photophobia are also common complaints of 
patients of acute encephalitis syndrome. Seizures are mostly seen among 
children. It occurs as a part of initial presentation of bacterial meningitis. 
Elevated intracranial pressure is an expected complication and a dangerous 
presentation of bacterial meningitis. More than 80% of patients will have 
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pressure of more than 180 mmH2O in the CSF. The worst thing in raising ICP 
is coning .The incidence of coning among patients with suspected bacterial 
meningitis is reported from the range of 1% to 7%8. 
Diagnosis 
  Blood cultures should be obtained immediately when bacterial 
meningitis is suspected. Diagnosis is made by the examination of CSF. The 
classic CSF abnormalities in bacterial meningitis are PMN increased white cell 
count, decreased glucose level, increased protein level, increased  pressure of 
CSF. bacterial cultures are positive in more than 70% of patients7  
CSF gram stain demonstrates more than 50% of patients. CSF glucose 
concentrations are abnormal in patients of meningitis. Serum/CSF, glucose ratio 
should be monitored for getting the diagnosis9. A 16s rRNA sequence broad 
based bacterial PCR can identify small numbers of viable and non viable 
organisms in CSF and is expected to be useful for making a diagnosis of 
bacterial meningitis in patients who have been admitted and treated with 
antibiotics and  where  gram stain and CSF culture are negative.9 
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 TABLE 1: CEREBROSPINAL FLUID ABNORMALITIES 
Pressure >180 mmH2O 
White blood cells 10µL to 10000 Μl 
Red blood cells Absent 
Glucose <40mg /DL 
CSF/serum glucose <0.4 
Protein >45 mg /DL 
Gram stain Positive >60% 
Culture Positive >80% 
PCR Detects bacterial DNA 
Limulus lysate Positive  in gram negative meningitis 
Latex agglutination Positive in S.pneumoniae,N. 
meningitides 
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Viral meningitis 
          Viral meningitis are caused by the infection or the inflammation 
produced by the viruses. This can be classified in to acute meningitis, sub acute 
meningitis and chronic meningitis. 
            Mostly viral meningitis are in acute stage with the complaints of head 
ache, temperature, vomiting, and decreased level of consciousness.  
           In Immunocompetent patients having viral meningitis normally presents 
with head ache, fever and signs of meningeal irritation together with an 
inflammatory CSF profile. 
            Head ache is the most common symptom almost invariably present in 
all cases which is often characterized as frontal or retro-orbital and is often 
associated with photophobia and pain when moving the eyes to the edges. 
            Neck rigidity is present in most of cases but may be mild and present 
only near the limit of neck extension   movements. 
Causative organisms are 
1. Japanese encephalitis virus  
2. Herpes simplex virus  
3. Entero virus 
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By using different diagnostic methods, including CSF PCR, culture, and 
serology, a precise viral cause can be found in most of the viral meningitis 
cases. In viral meningitis 75-90% of cases can easily diagnosed by cell culture, 
PCR, and serology9.  
The most important organisms producing meningitis are (HSV type-2) 
and arboviruses. CSF cultures results shows positive only in 30-70% of 
patients. Isolation of virus is mainly depends on the specific viral organisms 
and viral load. In the region of one-third of culture negative cases are classified 
as “aseptic” meningitis. 
 
Epidemiological features 
Viral meningitis is not a nationally notifiable disease; on the other hand it 
has been estimated that the yearly incidence of cases in world wide is about -
75000 per year/1 lakh populations5.  
There is a substantial increase of cases during the summer  reflecting 
which reflects the seasonal predominance of enetrovirus and arthropod-bone 
virus  infections . 
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Laboratory  diagnosis 
 Examination of cerebrospinal fiuid 
 On macroscopic appearance10 
       CSF appears clear in viral meningitis. The terminology aseptic 
meningitis most widely used to identify the viral meningitis.    
   On microscopic appearance 
       Minimal white blood cells normally present in CSF.  
Cell count analysis 
       The typical profile is an elevated count of lymphocytes                      
(5 to500cells/µl) and   increased  level of white cell count. 
Biochemical analysis 
             A normal or slightly raised protein level (10-100 mg/dl).  
            A normal glucose concentration or slightly decreased, and 
            A normal or mildly elevated opening pressure (100 to 
400mm H2O). 
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JAPANESE    ENCEPHALITIS 
    Family of flaviviridae of viral pathogens are classified into three 
groups. It includes pestivirus, flavivirus, hepacyvirus.  Flaviviruses are 
recognized by causing diseases among humans and animals.  Commonest 
flaviviral infections are dengue viral infection, West nile virus infection, 
Yellow fever virus infection, Japanese encephalitis virus infection  
.Flaviviral infections are mainly transmitted through vectors. Mosquitoes 
are the main vector in transmitting the infections, ticks are also playing role in 
transmitting the infection. 
 
Zoonotic disease 
Japanese encephalitis, yellow fever disease, dengue fever disease, 
together called as zoonotic diseases .This type of infections can be classified 
into two categories 1.enzoonotic 2.epizoonotic 
This zoonotic cycle needs pigs as the key amplifier, birds, ticks, 
mosquitoes are used as a carriers for the transmission of infection. 
 
Japanese    encephalitis 
• 25% of patients with JEV infection may die due to encephalitis 
complication.  
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• 50% of patients will develop neurological complications like 
memory impairment, paralysis, behavioral changes, seizures and 
impaired cognition. 
Humans are considered as dead end host due to low level of viremia in 
the blood circulation. Low level of viremia is insufficient to infect the feeding 
mosquitoes. 
Vectors  
Culex 
• It belongs to culex vishnui subgroup,which acts as a main vector 
for the transmission of Japanese encephalitis infection. 
• Anopheles barbirostris van der Walp and Anopheles subpictus 
have also been identified from India for harboring JEV 
Incidence  
• Incidence is about 45000 cases and 10000 deaths annually in world 
wide. 
• In 1871 the first case was identified in Japan afterwards tropical 
countries like south East Asia and north Australia6. 
• An epidemic occurs during summer period in north Asian region. 
• Peak infections can be seen during rainy season in south Asian 
region.   
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CLASSIFICATION OF FLAVIVIRUS 
 
FIG: 1 FLOW CHART OF CLASSIFICATION OF FLAVIVIRUS 
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                                                   JEV GENOME   
• Japanese encephalitis virus is an enveloped virus of 55nm in 
diameter size. 
• It has a single standard RNA virus with positive sense. 
• The RNA viral genome is 11kb in length. 
• It contains three structural proteins 
                      1.Precursor to membrane (prM) 
                       2. Envelope (E) 
                        3. Capsid (C). 
• .Non structural proteins 
                       NS1, NS2, NS3, NS4, NS5 
• 5 genotypes have been identified such as genotype I, II, III, IV 
and V  
• Hemagglutination test monoclonal antibody test and polyconal 
antibody test can be used to make a difference between the 
isolates within the same gene 
 
Precursor to membrane (prM) 
• Precursor to membrane protein is a Glycoprotein in nature having 
two trans membrane helices. 
• It serves as a chaperone to form E protein and for assembly of 
protein. 
• Maturation is taken place in Golgi apparatus 
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C protein  
• It has 120 amino acids and  it forms the homodimers in shape. 
• This protein   is involved in packaging of the viral genome and  
• It also involved in the formation of the neucleo capsid   prM  and E 
. 
E protein 
• Main intention of E protein is to form neutralizing antibodies, 
which contains receptor binding site for NS1. 
• It has the skill to induce the protective antibody secretion in the 
host 
NS-2B protein 
• NS-2B protein ruins as a heterodimer material along with NS-3 
protein and helps in anchoring of this heterodimeric complex to 
the endoplasmicreticulam membrane. 
NS3 protein  
• NS-3protein is participating in viral replication and viral assembly 
by its RNA helicase and NTPase activity.  
NS5 protein 
• This protein is the biggest among all the proteins of JEV.  
• It has methyl transferase activity on its N terminal end and RNA-
dependent RNA polymerase activity on c-terminal end. 
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Viral replication 
 
• Viral replication starts with entry of JE virus 
 
. 
• It enters in to the host cell by the mechanism of receptor 
endocytosis. 
 
 
• A viral replication complex is formed by NS3 and NS5. 
 
 
• By using replicating complex double standard replicative form is  
formed. 
 
• Replication force starts with the formation of RNA strands which 
is  complementary to the parent strand.. 
 
 
• Cyclization of viral genome confirms that replicated viral RNA is 
in full length. 
 
 
..  
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.
      
              FIG 2: LIFE CYCLE OF JAPANESE ENCEPHALITIS VIRUS  
 
 
 
. 
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. 
      
                                                                                
              FIG3:   GENOME OF THE JAPANESE ENCEPHALITIS VIRUS 
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                                               PATHOGENESIS 
 
• Data available for this viral encephalitis due to JEV has been 
derived from animal models and in vitro.  
 
• This JEV encephalitis starts with bite of infected mosquitoes. It 
has a peripheral replication cycle that we can see in vitro studies 
 
• Japanese encephalitis viral infection produces impairment of hot 
immune system which leads to functional reduction of differential 
count.  
 
• Differential count population is altered after JEV infection 
 
• Japanese encephalitis viral infection transmitted to central nervous 
system takes place mainly through antipodal transport. 
 
• Rough endoplasmic reticulum is the site of replication in neurons. 
 
• Infection of neuronal stem cells leads to loss of neurons in 
subvendricular zone. 
 
• Microglial cells  and  astrocytes acts as a scavenger cells in the 
site of neuronal injury. 
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FIG4:  REPLICATION OF JAPANESE ENCEPHALITIS VIRUS 
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CLINICAL FEATURES 
• Most of the Japanese encephalitis infections are asymptomatic. 
Symptoms are developed only with less than1% of the populations.  
• Infection principally affects children who are all age group of less 
than 15 years2 
• Incubation time is 5-15 days in Japanese encephalitis infection. 
 
• Symptoms 
             Fever 
            Head ache 
            Vomiting 
             Myalgia 
            Altered mental status 
             Seizure 
             Paralysis 
            Impaired cognition 
            Gastrointestinal symptoms of abdominal pain in children. 
• Most of the symptoms are due to cerebral edema and congested 
lepto meninges of brain tissue. 
.   
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FIG: 5 NEUROPATHOGENESIS OF JAPANESE ENCEPHALITIS 
VIRUS 
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 RESPONSE TO JEV INFECTION 
 IMMUNITY 
Humoral and cell mediated immunity  
• Immunity has a major role in Japanese encephalitis infection.  
• Antiviral antibodies have been reported as an imperative to deal 
with the arbovirus induced encephalitis.   
• Neutralization occurs though antibodies which will usually clear 
the cell free viruses.  Phagocytosis is taken place to clear the 
virion.  
• If there is any neuronal infection, antibodies are acted over the 
surface of infected neuron cells to alter intracellular replication of 
viruses with the aim of follow the non cytolytic mechanism. 
• Development of IgM antibodies after infection plays major role in 
the identification of Japanese encephalitis infection. 
• IgM antibodies can be identified in both serum and cerebrospinal 
fluid. 
• IgM antibodies can be detected in CSF on day 1. 
• In case of serum it will take 5 to 7 days. 
• Identification of IgG helps to cross check the other flaviviral 
infection. 
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STRAIN VARIABILITY  
JEV occurs as a single serotype, though considerable antigenic variation 
is observed. More than 50 strains being isolated in Japan alone. Five JEV 
genotypes have been described (GI–GV)22 , however genotype relationship to 
phenotype or virus fitness is still unclear. The basis for genotyping is 
phylogenetic analysis of the viral envelope E gene, vitally important in viral 
attachment and entry into host cells. A potential link does exist between JEV 
genotype and climate. GIa and GII are significantly associated with tropical 
climates, GIb and GIII with temperate climates, and GIV is confined 
geographically within Indonesia. Despite its current isolation, GIV is believed 
to be ancestral to all other circulating genotypes and shows the largest antigenic 
and phylogenetic difference of all the genotypes. GV has been found in both 
tropical and temperate climates and recently reemerged in Tibet and South 
Korea after remaining undetected for nearly 60 years. Since its reemergence, 
GV has shown a high capacity for dispersal in a short time period and also 
warrants continued monitoring given its potential for high virulence. At present 
GIb is believed to be the dominant JEV genotype throughout Asia23.  
 
CLEANING AND DISINFECTION  
 SURVIVAL  
The thermal inactivation point of JEV is 40˚C, and the virus can be easily 
destroyed completely by heating for 30 minutes at 56 ˚C. JEV is labile, 
sensitive to ultraviolet light and gamma radiation, and does not survive well in 
the environment. The virus is stable in alkaline environments (pH 7–9) and 
inactive in acidic environments.  
Seasonal precipitation, humidity, and temperature changes are thought to 
influence JEV transmission by affecting human agricultural practices and the 
life cycle of mosquito vectors. Higher humidity is a key factor, known to 
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influence longevity, mating, dispersal, and feeding behavior of mosquitoes. 
Environmental temperatures in the range of 22–34˚C have been shown to 
increase mosquito density,10 decrease larval development time, and reduce the 
extrinsic incubation period of the virus in mosquito vectors, affecting potential 
JEV transmission.  
                           In endemic areas, cases occur sporadically throughout the year 
with occasional increases during the rainy season. JEV express more epidemic 
viral activity in northern temperate Asian climates, with disease outbreaks in 
summer months. Subtropical regions, such as Thailand and Vietnam, may see a 
combination of epidemic and endemic disease characteristics21. Year-round 
maintenance of JEV in temperate climates is thought to occur by overwintering 
mosquitoes, poikilothermic vertebrates, hibernating bats, and/or by vertical 
transmission from female mosquitoes to offspring. Annual re introduction into 
temperate climates by migrating birds, bats, or wind-borne mosquitoes is also a 
possibility, though phylogeny studies of JEV genotypes suggest more local 
rather than widely dispersed cycles of transmission. Genotypes in tropical 
climates are maintained year-round by traditional vector-host transmission 
cycles. 
 
Disinfection  
Disinfection can be achieved with organic and lipid solvents, common 
detergents, iodine, phenol iodophors, 70% ethanol, 2% glutaraldehyde, 3–8% 
formaldehyde, or 1% sodium hypochlorite25. 
 
EPIDEMIOLOGY  
 SPECIES AFFECTED  
Pigs are the main amplifying host of JEV, exhibiting high and prolonged 
viremia and a natural infection rate of 98–100%26. Reproductive failure is a 
trademark of the clinical disease in pigs, and total losses can reach 50% or 
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more.JEV infection in humans, predominantly children and travelers from non-
endemic areas who have not developed immunity to the virus. Sporadic 
encephalitis is observed in horses, and the virus is manifested either as severe 
encephalitis or more commonly as subclinical infection. In horses, the mortality 
rate is not about 5% 25.Neither humans nor are horses believed to contribute to 
virus transmission due to their relatively low titers and short-term viremia. 
Subclinical infection has been reported in cattle, sheep, goats, dogs, cats, 
chickens, ducks, wild mammals, reptiles and amphibians, but these species are 
not known to contribute to spread of the disease.  
 
ZOONOTIC POTENTIAL  
JEV is a zoonotic disease persisting in nature through a cycle of 
transmission primarily between mosquitoes, some domestic and wild birds, 
domestic and pigs, and humans. Humans can become infected with the virus, 
sometimes fatally, but are considered dead-end hosts. Amplification of JEV in 
swine often precedes human epidemics. A recent multi-criteria decision 
analysis (MCDA) conducted in Australia found JEV, along with rabies, Nipah 
virus, and Eastern equine encephalitis, to be the highest priority diseases in the 
swine industry when considering zoonotic criteria alone. In regions where the 
virus exists, several key characteristics influence human infection risk: the 
density, size, and spatial organization of rice paddies, swine farms, and human 
communities. 
 
GEOGRAPHIC DISTRIBUTION  
JEV is endemic in much of Asia and the Pacific, encompassing regions 
occupied by nearly half of the human population1. The greatest population 
density in endemic areas can be found in India and China, though the disease 
has been reported as far west as Pakistan, as far south as northern Australia and 
Papua New Guinea, as far north as maritime Siberia, and as far east as the 
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island of Saipan.The potential for JEV to spread quickly upon introduction into 
new areas, similar to closely related WNV in 1999, is a public health concern27. 
Recent isolation of genetic material of JEV in birds and mosquitoes in Italy 
further substantiates the need for continued vigilance. 
 
MORBIDITY AND MORTALITY  
Rates of JEV infection are higher in animals than humans, and 
detrimental biological and economic consequences in swine production arise 
primarily from reproductive failure and high piglet mortality. The mortality rate 
in infected piglets with no immunity to JEV is near 100%, while mortality in 
infected adult swine is close to zero. Reproductive losses can reach 50–70%. In 
humans, JEV is the greatest known cause of epidemic viral encephalitis 
worldwide and more than one-third of the world’s population is at risk of 
infection. The virus primarily affects children; on the other hand less than 1% 
of JEV infections in humans actually progress to encephalitis22. An estimated 
50,000 documented human cases of JEV occur annually, resulting in at least 
15,000 deaths22. Due to the lack of surveillance and data collection in many 
areas, the actual incidence may be much higher. Up to half of those infected can 
suffer permanent neurologic damage33, 45. 
 
TRANSMISSION  
JEV relies on vector-borne transmission. Wading water birds (such as 
herons and egrets) are the primary natural reservoirs of the virus, while pigs act 
as amplifying hosts. Over 90 bird species are known to be amplifying and 
reservoir hosts of JEV32, capable of wide virus distribution and introduction 
into new areas. Additional proposed amplifying hosts include orangutans and 
bats, dogs, and flying foxes have also exhibited seropositivity for anti-JEV 
antibodies. Known vectors include Culex mosquito species, primarily Cx. 
tritaeniorhynchus, as well as Cx. fuscocephala, Cx. annulirostris,Cx. annulus, 
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Cx. sitiens, and potentially Cx. quinquefasciatus. Other important regional 
vectors include Cx. vishnuiin India and Cx. gelidusin Indonesia. In addition to 
the preferred Culexspecies, Anopheles sinensisand Aedesalbopictusare known 
vectors, along with several Armigeresand Mansoniaspecies. Potential natural 
JEV vectors, Cx. pipiens, Cx. Quinquefasciatus34. 
                     Epizootics involving swine appear to be cyclical, consisting of two 
separate amplification cycles. During the first cycle, roughly 19% of pigs will 
become infected and develop antibodies within ten days30. This is followed by a 
second cycle, one to two weeks later, in which mosquitoes transmit the virus to 
remaining naïve pigs effectively raising the rate of sero conversion to almost 
100%. Clinical cases in humans typically occur following this cycle of 
amplification in swine. As each extrinsic incubation period in mosquitoes 
ranges from 5–15 days, it can take up to 30 days for the virus to complete its 
infection process in humans. In addition to natural transmission cycles, 
attention is also given to artificial insemination practices in modern swine 
production.  
                       JEV is known to cause inflammation of the genital tract in boars, 
which can lead to subsequent shedding of the virus in semen and possible 
transmission to breeding sows. Laboratory-acquired JEV infection has been 
reported in humans, and work with the virus is restricted to Biosafety Level 3 
(BSL-3) facilities and practices. Transmission can occur through needle sticks 
and potentially at mucosal surfaces if exposed to high concentrations of 
aerosolized virus. 
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INFECTION IN SWINE/PATHOGENESIS  
CLINICAL SIGNS  
Reproductive failure is the most common clinical manifestation in swine. 
Sows may give birth to stillborn, mummified, or darkened fetuses, and boars 
may experience reduced number and motility of sperm. Testicular edema and 
temporary infertility in boars has also been observed. 
 
POSTMORTEM LESIONS  
Gross lesions of affected piglets include hydrocephalus, cerebellar hypoplasia, 
subcutaneous edema, and spinal hypo myelinogenesis. Multifocal hepatic and 
splenic necrosis may also be seen grossly, while histological lesions are 
generally restricted to the central nervous system. Serosal petecchiae, bicavitary 
effusions, neuronophagia, glial nodules, and perivascular cuffing in the brain 
and spinal cord have also been observed.35 
 
DIAGNOSIS  
CLINICAL HISTORY  
Reproductive failure is the most common manifestation of the disease, 
and there are no characteristic gross lesions of infected sows. JEV infection 
prior to 50–70 days of gestation can cause abortion, fetal mummification or 
stillbirth, and encephalitis in young animals35. In endemic areas, the breeding 
impact may actually be seen more in boars than sows. Some sows may be able 
to develop protective immunity prior to reaching sexual maturity, whereas 
earlier maturing boars are at risk of infertility if they have not yet developed 
protective immunity. 
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TESTS TO DETECT NUCLEIC ACIDS, VIRUS, OR ANTIGENS  
Virus isolation, though time consuming, is the gold standard for a 
definitive diagnosis. To isolate the virus in laboratory animals, tissue 
homogenates from infected animals are first inoculated intra cerebrally into two 
to four day old mice. If the mice show neurological signs, followed by death 
within 14 days, their brain tissue is collected for a second passage in mice. At 
this stage, if viral antigen collected from the brain tissue supernatant of infected 
mice is able to agglutinate red blood cells of one-day-old geese or chickens, it is 
then available for use in hemagglutination inhibition (HI) testing with JEV 
antiserum. Primary cultures can be used, inoculated either with tissue directly 
from infected swine or brain suspension from inoculated mice. A variety of cell 
lines are suitable; the Aedesalbopictus mosquito cell line C6/36 is useful, as are 
chicken embryo, African green monkey kidney (Vero) cells, baby hamster 
kidney (BHK) cells, and porcine kidney (PSEK) cells. Cytopathic effect may 
not be observed in C6/36 cells, requiring further culture or other diagnostics 
(such as detection of antigen or RNA). Following culture, indirect 
immunofluorescence can be used to identify the viral antigen using monoclonal 
antibodies to JEV specifically or flaviviruses in general. Isolated virus can also 
be identified by reverse transcription polymerase chain reaction (RT-PCR) or 
serological methods. 
         RT-PCR is routinely used in diagnostic laboratories, and both 
conventional and real-time assays are available. Several multiplex PCR 
(multiplex PCR) assays have been developed for simultaneous detection of six 
common diseases of swine—pseudo rabies virus (PRV), porcine parvovirus 
(PPV), porcine circo virus (PCV) type 2, porcine reproductive and respiratory 
syndrome virus (PRRSV), classical swine fever virus (CSFV), and JEV—in a 
single reaction system. Additional reduction of cost and overall assay time is 
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achieved with multiplex real-time PCR. Sensitivity remains higher with single 
PCR; however multiplex tests have high specificity for each individual virus. 
       An additional testing method of interest is multiplex ligase 
detection–polymerase chain reaction and microarray (MLPM). MLPM has been 
described for the simultaneous detection of PCV, PRRSV, CSFV, PPV, PRV, 
and JEV. This test shows a high degree of specificity, more rapid diagnostic 
time, and enhanced sensitivity compared to real time RT-PCR, as well as 
modification capacity to include additional pathogens41. A nucleic acid 
detection method, the reverse transcriptase-loop-mediated isothermal 
amplification (RT-LAMP) assay, has been described for detection of viral 
RNA, though veterinary application is still limited. One-step real time RT-
LAMP assays are experimentally proven to have sensitivity equal to real time 
RT-PCR and greater than conventional RT-PCR in targeting the NS1 gene of 
JEV. Real time RT-LAMP also demonstrates greater sensitivity than 
conventional RT-PCR in targeting the highly conserved NS3 gene. Additional 
targets in RT-LAMP assays are the E genes of JEV genotypes I and III. This 
method demonstrates a ten-fold increase in sensitivity compared to 
conventional RT-PCR.  
                      Genotypes I and III can be differentiated with RT-LAMP by 
targeting a single nucleotide polymorphism located in the capsid C gene, and 
RT-LAMP coupled with a lateral flow dipstick (LFD) is able to detect multiple 
strains of JEV and eliminate the need for potentially unstable fluorescent dyes. 
                     A high degree of specificity can be achieved with RT-LAMP 
assays, showing no cross-reactivity with other clinically and/or serologically 
related swine diseases. Given the efficacy, simplicity, and speed of these 
assays, they are a potentially desirable option for field-level testing and 
accommodation of a large number of samples.Flavivirus-specific monoclonal 
antibodies (MAb) can detect JEV antigen in serum, and immunohistochemistry 
can be used to detect JEV antigen in fetal tissues.  
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                           Antigen capture enzyme-linked immunosorbent assay (ELISA) 
has been developed for simple and rapid detection of JEV infection, as an 
alternative to virus isolation and RT-PCR. M Ab against the E protein is used 
for its high specificity to JEV, followed with a polyclonal antibody (PcAb) 
conjugate to enhance sensitivity and detection of multiple strains. It is important 
to note that sensitivity is slightly higher with RT-PCR, and antigen capture 
ELISA may be unable to detect very low viral loads.44 
 
TESTS TO DETECT ANTIBODY  
A variety of serological tests are available to establish the prevalence of 
infection in a population or to make a diagnosis in a diseased individual. 
Methods include immunofluorescent antibody (IFA), virus neutralization (VN), 
hemagglutination inhibition (HI), complement fixation (CF), and ELISA. The 
VN test is specific, enabling the greatest differentiation between JEV and other 
flaviviruses. JEV, typically the Nakayama or JaGAr-01 strain, is propagated in 
cell culture using chicken embryo, Vero or BHK cells for the preparation of 
aliquots of virus-containing supernatant. 
 Hemagglutination inhibition is widely used, despite its cross-reactivity 
with other flaviviruses45. A four-fold difference in titer between serum samples 
from acute and convalescent phases is sufficient for diagnosis of flavivirus 
infection, though not necessarily JEV .A faster more efficient potential 
alternative to HI is a newly developed immunochromatographic test for the 
detection of anti-JEV IgG in pig serum.  
For this test, domain III of the JEV E protein, known to be bound by anti-
JEV antibodies, is expressed in soluble form in a bacterial expression system. 
This eliminates the need for erythrocytes and mouse brain-derived JEV antigen. 
Immunochromatographic assays have already been used for the detection of 
avian influenza, PRRSV, and PCV, as well as contagious diseases in humans.  
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    Complement fixation is rarely used for diagnosis by combining test 
serum, antigen extracted from inoculated mouse brains with acetone, and 
pooled fresh guinea pig serum (complement). The highest test serum dilution 
where no hemolysis occurs is the titer for this particular test, and a four-fold 
change in titer is considered to be significant for diagnosis. The IgM capture-
ELISA (MAC-ELISA) is commonly used11. IgM can be detected within two to 
three days and for up to three weeks post-infection in pigs. To distinguish 
between antibodies from natural infection and antibodies to inactivated 
vaccines, ELISA detection of antibody to the nonstructural NS1 protein of the 
virus is utilized. 
 The interpretation of serological results, especially in older pigs, must 
consider vaccination history and age; maternal antibody can persist for up to 
eight weeks. It is also important to note that there is some level of cross 
reactivity with other flaviviruses for all of the serological tests.  
 
SAMPLES 
 REJECTION CRITERIA 
1. Insufficient volume. 
2. Specimens in leaky containers   
           3. Possibility of contamination 
 
Infected tissues are preferred for virus isolation, as isolation from blood 
and cerebrospinal fluid is occasionally achieved21. Due to the uneven spread of 
viral pathogens among fetuses in utero, it is important to sample tissue from an 
adequate number of fetuses.  
In general, four to six should be sampled to avoid missing a diagnosis.  
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The OIE recommends brain or spinal cord be sampled, though spleen, 
liver, or placental tissues from stillborns, neonates, or fetuses may also be 
acceptable RT-PCR can identify the virus in cerebrospinal fluid, sera, and tissue 
culture supernatants. 
 Recent multiplex PCR tests for detection of multiple diseases of swine 
have used tissue homogenates from lung, spleen, kidney, and lymph nodes of 
aborted fetuses or pigs displaying clinical signs of disease. The ability to detect 
low levels of the virus in blood samples of newly infected swine can be 
achieved with the real time RT-LAMP assay.  
Antigen capture ELISA is able to detect JEV in cerebrospinal fluid, brain 
tissue, and mosquito homogenate, and detection of anti-JEV antibodies in 
serum, thoracic, or abdominal fluid of stillborn piglets is also considered 
diagnostic32. 
 Classically, any serological tests should include paired samples to 
demonstrate a rise in titer from acute to convalescent phases of disease. The use 
of oral fluids as a diagnostic specimen has not been evaluated for JEV.  
 
IMMUNITY  
POST-EXPOSURE  
Natural infection contributes to long lasting immunity in adult pigs and 
surviving piglets. The host immune system primarily targets the E protein, a 
viral envelope glycoprotein consisting of three structural domains. 
VACCINES  
Currently, complete control and eradication of JEV by vaccination is 
implausible. Vaccination of swine can decrease amplification of the virus; 
though, regular vaccination of piglets can be cost prohibitive and maternal 
antibodies can decrease effectiveness of the existing live-attenuated vaccine. 
 Existing live-attenuated swine and human vaccines are GIII-derived and 
elicit greater GIII strain-specific neutralizing antibodies.  
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The E protein of JEV is critical in neutralizing antibody responses and is 
also the basis for separation of JEV into different genotypes.  
Some level of protection using current vaccines is still observed against 
GI strains, possibly aided by a T cell response induced by vaccination. 
 There is still no specific treatment for Japanese encephalitis, and 
alternative vaccination methods are being developed. In spite of their 
limitations, vaccines can help to prevent JEV infection in humans and animals. 
 Efforts have been made to develop bivalent and multivalent vaccines as 
a time and cost-saving measure. 
 An experimental recombinant pseudorabies virus (PRV) vaccine 
expressing the NS1 protein of JEV has been shown to induce long lasting 
antibody against JEV as well as cell-mediated immunity in piglets.  
Pigs receiving simultaneous intradermal and oronasal vaccination with an 
experimental chimeric classical swine fever (CSF)-JEV virus replicon particle 
(VRP) exhibit more rapid anti-JEV IgG and neutralizing antibody responses 
than those vaccinated subcutaneously with a commercial inactivated vaccine. 
 Viremia is also undetectable or transient in challenge studies with the 
VRP vaccinated pigs. In its place is a gene expressing domain III of the 
antigenic JEV E protein. 
 Inactivated and live-attenuated vaccines are available in some countries 
for pregnant sows to increase chance of live births and for breeding boars to 
protect against reduction or deformity of sperm. 
 The live-attenuated vaccine has shown greater efficacy than the killed 
vaccine in both experimental and naturally occurring infection and an 
obtainable trivalent vaccine offers combined protection against JEV, PPV, and 
Getah virus (GETV). 
 Attributable to the genotypic shift from predominantly GIII to GI in 
large parts of Asia in the last decade, efficacy of some existing vaccines may 
need to be reevaluated. 
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 In a study of weaned piglets receiving live-attenuated JEV vaccine 
protective against GIII, only limited cross-reactive protection against GI was 
observed. It is possible to increase the immunogenicity of existing vaccines 
with the use of novel adjuvants. 
 Specifically, an inactivated JEV GI vaccine containing the cytokine 
recombinant porcine granulocyte-monocyte colony stimulating factor (rGM-
CSF) has been shown to augment humoral immunity in pigs. 
 Live-attenuated vaccines can be difficult and costly to produce and carry 
associated bio safety concerns. 
 Efforts are happening to develop stable cell lines capable of 
continuously expressing JEV virus-like particle (VLP) antigens that can 
effectively induce neutralizing antibodies to JEV. 
 One such cell line, BJ-ME, produced JEV VLPs able to induce high 
titers of neutralizing antibodies and complete protection in mice exposed to 
lethal JEV challenge.  
Experimental DNA vaccines have also shown some ability to induce high 
antibody titers and have potential to be advantageous in swine production. 
 Proteins expressed from plasmids encoding the JEV E genes associate to 
form particles, similar to VLPs, effective in eliciting neutralizing antibody and 
cytotoxic T lymphocyte (CTL) responses in mice.  
These same plasmids also elicit a higher neutralizing antibody response 
than the inactivated vaccine in swine, with antibodies persisting for up to eight 
months post-vaccination. 
 
CROSS-PROTECTION  
Cross-protective antibody responses have been induced experimentally in 
pigs exposed to closely related flaviviruses, suggesting the potential for 
prevention or inhibition of JEV infection in areas where multiple flaviviruses 
are endemic.  
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Though, the coexistence of JEV with MVEV in Papua New Guinea and 
WNV in Pakistan suggests that adequate numbers of susceptible hosts may 
exist to accommodate multiple viruses. 
 Of the three domains of the immunogenic E protein component of the 
JEV viral envelope, flavivirus cross-reactive epitopes are found predominantly 
in domain II.  
Until now, neutralizing epitopes have been mapped in domain III, 
showing a high level of conservation between multiple strains of JEV and 
WNV, suggesting some level of cross-protection43. 
 
PREVENTION AND CONTROL  
Successful decline of JEV in endemic areas has been attributed to large 
scale human immunization, immunization of pigs, separation of pigs from 
human communities, alterations in agricultural practices to reduce the presence 
of mosquitoes, and better overall standards of living.  
Other examples of preventative measures include removal of stagnant 
water around pig enclosures, insecticides, insect screens, and use of fans inside 
buildings where pigs are housed to disrupt mosquito activity.  
In pigs that do become infected, alpha interferon (IFN-α) shows promise 
as an antiviral treatment method able to experimentally increase expression of 
interferon-stimulated genes with strong anti-JEV effect.  
There are recommendations for importation of horses from countries or 
zones infected with JEV, but no recommendations for importation of swine.  
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TABLE 2: INCIDENCE OF CASES AND DEATHS IN INDIA 
                        
 
 
 
s.no states 2004 C/D 
2005 
C/D 
2006 
C/D 
2007 
C/D 
2008 
C/D 
2009(P) 
C/D 
2010(P) 
C/D 
1 
Andra 
 
7/4 34/1 11/1 22/1 6/1 13/1 131/1 
2 
Assam 
 
235/45 145/50 392/88 424/99 319/99 462/92 274/97 
3 Bihar 
 
85/25 190/62 21/3 336/164 204/45 325/95 19/0 
4 Haryana 
 
37/25 46/39 2/2 32/18 13/2 12/11 0/0 
5 Karnataka 182/6 122/10 73/2 32/1 3/0 247/8 
- 
6 Kerala 9/1 0/0 3/3 1/0 2/0 3/0 19/0 
7 
Maharashtra 
 
22/0 51/0 1/0 0/0 24/1 1/0 0/0 
8 Manipur 
 
0/0 1/1 0/0 66/1 4/0 6/0 111/6 
9 Nagaland 
 
0/0 1/1 1/1 7/0 0/0 9/2 11/5 
10 Punjab 0/1/1 1/0 0/0 1/0 0/0 0/0 
- 
11 Uttarkanad 0/1 1/1 1/2 2/2 12/1 0/0 
- 
12 Tamilnadu 88/9 51/11 18/11 37/1 144/1 266/7 242/3 
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MATERIALS AND METHODS 
 
APPROVAL OF THE ETHICAL COMMITTEE 
        This study was approved by the ethical committee of our institute and 
informed consent was obtained from all patients who are included in this study 
. 
PERIOD OF STUDY 
         This study was conducted over a period of one year from May 2015 to 
April 2016. 
PLACE OF STUDY 
It was carried out in the Department of Microbiology, Thanjavur Medical 
College. 
COLLABORATING DEPARTMENTS 
         This study was conducted in collaboration with Department of Medicine, 
Thanjavur Medical College Thanjavur and Department of Pediatrics, 
Government  Raja Mirasudar Hospital Thanjavur. 
 
DESIGN OF STUDY 
It was cross sectional and comparative study. 
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MATERIALS  
This study was included 100 patients. A total of 100 patients who were 
admitted Department of Medicine, Thanjavur Medical College  and Department 
of Pediatrics, Government  Raja Mirasudar Hospital Thanjavur were included 
in this study during the period from May 2015 to April 2016.  CSF sample was 
collected from each patient with all age groups. Furthermore basic demographic 
characteristics such as age, sex, socio economic status and place were also 
obtained 
 
METHODOLOGY: 
           This is cross sectional and comparative study that aims to analyze 100 
cases of clinically diagnosed meningoencephalitis, admitted in thanjavur 
medical college hospital.  CSF   samples for cytological, biochemical  analysis, 
antibody detection by IgM capture ELISA method, and molecular 
characterization of JE virus to be done by RT-PCR in serologically positive 
cases. . 
INCLUSION CRITERIA: 
Patients clinically diagnosed as acute encephalitis syndrome suspected 
Japanese encephalitis. 
 Fever 
 Headache 
 seizure 
 Vomiting 
 Neck rigidity 
 Hemiparesis 
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EXCLUSION CRITERIA: 
• Already diagnosed positive JE cases 
• Clinically diagnosed as non-infectious causes. 
• TB Meningitis. 
• Fungal meningitis 
• Parasitic meningitis 
 
CSF 
SPECIMEN COLLECTION  
LUMBAR PUNCTURE 
          To disinfect the puncture site, antiseptic solution and alcohol is used to 
clean the site. Gloves and mask was used  when doing the procedure.  
           A needle with stylet is inserted at the L3-L4, inter space. While the 
subarachnoid space is reached, stylet is removed; spinal fluid appeared in the 
needle hub. 
           Measurement of the hydrostatic pressure with a manometer is taken. 2ml 
of CSF is collected into 3 sterile labeled tubes. Collected samples were 
immediately to the laboratory and processed. 
 
VENTRICULAR SHUNT FLUID 
  Site is cleaned with antiseptic solution prior to removal of fluid and to 
prevent the introduction of infection. Cerebrospinal fluid is aspirated from the 
ventricular drain or shunt. 
 CSF is collected into a minimum of 3 sterile tubes. An initial CSF 
sample is collected before the administration of antibiotic therapy for diagnostic 
sensitivity.  
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Consequent CSF samples are collected every 2 to 3 days after 
antimicrobial therapy is started to monitor for resolution of the infection. 
 
SPECIMEN TRANSPORT 
Collected samples are labeled properly. Then labeled samples are 
transported to the laboratory immediately along with proper requestion.one 
sample is not refrigerated for bacterial culture processing and other two samples 
are refrigerated for cytological, biochemical analysis, antibody detection by 
serological method and for molecular study.. 
 
CSF PROCESSING 
3 containers to be used 
 One sample is used for bacterial identification, not to be refrigerated. 
 One sample is used for viral identification, to be refrigerated. 
 One sample is used for biochemical analysis and cell count analysis. 
 
 
PERFORMANCE SPECIFICATIONS: 
 
Neonates less than 28 days: E.coli, Group B streptococci 
Less than two months: Group B streptococci . 
Less than10 yrs:   H. influenzae, pneumococci 
More than 10yrs:  S. pneumoniae,Neisseriameningitidis 
Immunocompromised : Cryptococcus neoformans 
CNS shunt infection :  (CONS) 
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ON DAY I 
APPEARANCE OF CSF 
Clarity of CSF –noted. 
Noted for blood. 
Noted for clot. 
 
CENTRIFUGE CSF 
Centrifugation done for samples collected less than 1ml-vortex 30 seconds 
Centrifugation done for samples collected more than 2ml-3000rpm for 20 min. 
WET MOUNT EXAMINATION 
Examined for pus cells, RBCs, bacteria and yeast cells. 
India ink stain examination done to identify the capsulated organisms 
GRAMS STAIN 
 1-2 drops of CSF is used for the smear preparation.  
Dried the slide at free air 
Fixed the smear with methanol or heat 
Noted for pus cells, bacteria and yeast cell 
CULTURE  
Chocolate agar (CHOC), 
Blood agar,  
MacConkey agar 
RCM broth were used . 
Incubated at 37ºC for 48 hours; examined daily. 
 
ON DAY II 
CULTURE EXAMINATION: 
Examined all plates and Medias for macroscopic evidence of growth at 
24hours. 
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JEV DETECT IgM ANTIBODY CAPTURE ELISA (MAC_ELISA)  
SUMMARY AND EXPLANATION OF THE TEST 
               Exposure to JEV causes a disease with a number of symptoms   
Including meningitis and encephalitis. JE Detect   IgM  Antibody  Capture  
ELISA(MAC-ELISA)  employs  a  recombinant   antigen  called  JERA, which  
can  be  used  as a  rapid  serological  marker for  JEV  infection. The  JERA  
protein  is  a  recombinant  antigen, which  consists  of  a  stretch  of  peptides  
from  different parts  of the  JEV. 
PRINCIPLE OF THE TEST 
The  JE Detect   IgM  Antibody  Capture  ELISA(MAC-ELISA)  consists  
of  Detect  IgM  Positive  Control (represents  reactive  serum),and unknown  
serum  samples  are diluted  with  Sample  Dilution  Buffer, then  incubated  in  
micro titration  wells  which  have  been  coated  with  anti-human IgM 
antibodies. This is  followed  by  incubation  with  both  JEV- derived  
recombinant  antigen (JERA)  AND  Normal  Cell  Antigen(NCA) discretely. 
After  incubation  and  washing ,the  wells  are  treated  with  a  JERA-specific  
antibody  labeled  with  the  enzyme  horseradish  peroxidase .After  a  third  
incubation  and  washing step, the wells  are  incubated  with  
the(TMB)substrate. An  acidic  stopping  solution  is  then  added  and  the  
degree  of  enzymatic  turnover  of   the  substrate  is  determined  by  
absorbance  measurement  at  450  nanometers. Above  a  certain  threshold, the  
ratio  of  the  absorbencies  of  the  JERA  and  the  control  wells  accurately  
determines  whether  antibodies  to  JEV  are  present. 
PROCEDURE  1.Positive  and  Negative  controls  should  be  assayed  in  
duplicate  for  both  JERA  and  NCA  portions of assay. Unknown  serum  
samples  to  be  tested  can  be  assayed  singly  or  in  duplicate  but  must  be  
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assayed  for  both  JERA  and  NCA  portions  of  assay. Up  to  forty-four  
specimens  can  be  tested  on  one  96-well  plate. 
2. Mark the micro titration strips to be used. 
3.Diluted  test  sera  and  controls  to 1/100  using  the  provided  Sample  
Dilution  Buffer. Used  small  polypropylene  tubes  for  these  dilutions  and  
atleast  4µL  of  sera  and  positive  and  negative  control.  
4.Applied  the  50µL/well  of  1/100  diluted  test  sera, JE Detect   Negative  
Control, and  JE  Detect   Negative  Control  to  the  plate  by  single  or  multi-
channel  pipettor  as  appropriate. An perfect arrangement is shown below. 
Cover  the  plate  with  parafilm  or  similar  cover  just  on  the  well  opening  
surface, so  the  bottom  of  the  plates  is  not  covered.   
5.Incubated  the  plate  at  37 C  for  1  hour  in  an  incubator. 
Do not stack plates on top of each other. They should be spread out as a single 
layer. This is very important for even temperature distribution. Do not use CO2 
or other gases. Do  not  place  plates  in  contact  with  any  wet  substances  
such  as wet  paper  towel .   
CORRECT METHOD 
6.After  the  incubation ,wash  the  plate  6  times  with  an  automatic  washer 
using  Wash  buffer. Use 300 µL per well in  each  wash cycle. 
7.Added  50 µL /well  of  JERA  into  row  A-D  and  50µL/well  of  NCA  into  
row  E-H  by multi-channel  pipettor. A correct application for JERA  and  
NCA  shown  below. 
8.Covered  the  plate  with  the  parafilm  or  imilar  cover  just on  the  well  
opening  surface, so  the  bottom  of  the  plate  is  not  covered. 
9.Incubated  the  plate at  37ºC  for  1  hour  in  an  incubator. 
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10.After  the  incubation, washed  the plate 6 times  with  an  automatic  plate  
washer  using  1LWash  buffer. Used 300 µL   per well in each wash cycle. 
11.Added  50µL/well  of  ready  to  use  Enzyme-HRP  conjugate  into  all  
wells  by  multi channel pipettor. 
12.Covered  the  plate  with  the  parafilm  or  similar  cover  just  on  the  well  
opening  surface  ,so  the  bottom  of  the  plate  should  not  be  covered. 
13.Incubated  the plate  at  37ºC  for  1  hour  in  an  incubator  in  darkness. 
14.After  the  incubation, washed  the  plate  6  times  with  an  automatic  plate  
washer  using  1µWash  buffer. Use 300µL per  well  in  each  wash  cycle. 
15. Added 150 µL/well of EnWash into all wells by multichannel   pipettor. 
16.Incubated  the  plate  at  room  temperature  for  5  minutes  without  any  
cover   on  the  plate. 
17.After  the  incubation, washed  the  plate  6  times  with  an  automatic  plate  
washer  using  1 Wash  buffer. Use 300 L per well in each wash cycle. 
18.Added  75 µL/well  of  Liquid  TMB  substrate  into  all  wells  by  
multichannel  pipettor. 
19.Incubated  the  plate  at  room  temperature  in  a  dark  place  (or  container) 
for  10  minutes  without  any  cover  on  the  plate. 
 20.After  the  incubation, added  50µL/ well  of  Stop  solution  into  all  wells  
by  multi channel pipettor. 
22.Within  5  minutes, read  the  RAW  OD  450  value  with  a  Microplate  
reader. 
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CSF   SAMPLE: 
       Undiluted CSF samples were used. CSF sample optimization was done to 
get the proper dilution factor. The  rest  of  the  process  was  the same  as  
described  for  serum. 
         Necessary validation of CSF to be followed in laboratory before 
processing the unknown samples. 
 
 QUALITY   CONTROL 
Each  kit  contains  positive  and  negative  control  sera  to  ensure  assay  
performance. The  negative  and  positive  controls  are  intended  to  monitor  
for  substantial  reagent  failure. The positive control will not ensure précising 
at the assay cut-off. The  test  is  invalid  and  must  be  repeated  if  the  ISR  
values  of  either  of  the  controls  do  not   meet  the  specifications. 
Acceptable  Immune  Status  Ratio(ISR)  values  for  these  controls  are  found  
on  the  specification   table  below. If the test is invalid, patient results cannot 
be reported.  
 
CALCULATIONS FOR UNKNOWN SAMPLE ANALYSIS 
CALCULATION OF  THE  IMMUNE  STATUS RATIO(ISR): 
                Calculated  the  average  JERA   and  NCA  OD          values  for  
each  of  the  controls.  Test  samples  ran  in  singlet and obtained  the  
individual  JERA  and  NCA  values.  
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                Determined  the  Immune  Status  Ratio(ISR)  value  for  the  controls 
and  all  test  sera  by  dividing  the  JERA  OD      /NCA  OD .     
               The  assay  performance  is  deemed  valid  when  the  ISR  for  the  
positive  control  is  greater  than6.0, and  the  ISR  for  the  negative  control  is  
less  than  2.8. 
 
SELECTION OF THE CUT-OFF: 
          The  cut-off  was  selected  using  values  from  a  small  set  of  field  
data  and  is  an  estimate  only. 
Negative control JERA/NCA ratio more than 2.8 shows the test 
procedure is invalid 
Positive control JERA/NCA ratio less than 5.0 shows the test procedure 
is invalid 
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 TABLE: 3 ELISA INTERPRETATIONS 
 
 
ISR 
 
RESULTS 
 
INTERPRETATION 
 
Less than 4 
 
Negative 
 
No detectable antibody 
by the test 
 
4-6 
 
Equivocal 
 
Need confirmatory test 
 
Above6 
 
Positive 
 
Indicates the presence of 
detectable antibodies 
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REAL-TIME PCR DETECTION OF JEV 
MATERIAL & METHODS:  
PureFast® Viral nucleic acid mini spin purification kit [Kit contains Proteinase-
K, Lysis 
buffer, Wash Buffer-1, Wash Buffer-2, Spin columns with collection tube and 
elution buffer. 
HELINI JEV Real-time PCR kit is from HELINI Biomolecules, Chennai, India. 
 
REAL-TIME PCR MODEL: AGILENT MX3000P, USA 
HELINI Dengue virus [Universal] Real-time PCR kit components: 
RT-PCR Probe PCR Master Mix 
RT-Enzyme mix 
JEV Primer Probe Mix 
Internal control Primer Probe Mix 
Internal control template 
Positive control 
Instruction manual 
 
VIRAL RNA PURIFICATION 
1. 200µl of Plasma/serum transferred into fresh 1.5ml centrifuge tube. 
2. 200µl Viral lysis buffer added. 
3. Mixed well by vortex 
4. Add 20µl of Proteinase K and 5µl of internal control template, Mixed well by 
inverting several times. 
5. Incubate at 56ºC for 15min. 
6. Added 220µl of Ethanol and mixed well. 
7. Transferred entire sample into the Purefast® spin column. Centrifuged at 
10000rpm for 1min. Discard the flow-through and place the column back 
into the same collection tube. 
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8. Added 500µl Wash buffer-1 to the Purefast® spin column. Centrifuge at 
10000rpm for 1min and discard the flow-through. Place the column back 
into the same collection tube. 
9. Added 500µl Wash buffer-2 to the Purefast® spin column. Centrifuge a 
10000rpm for 1min and discard the flow-through. Place the column back 
into the same collection tube. 
10. Discard the flow-through and centrifuge for an additional 1 min. This step is 
essential to avoid residual ethanol. 
11. Transferred the PureFast® spin column into a fresh 1.5 ml micro-centrifuge 
tube. 
12. Added 60µl of Elution Buffer to the center of Purefast® spin column 
membrane. 
13. Incubate for 1 min at room temperature and centrifuge for 2 min. 
14. Discard the column and store the purified DNA at -20°C. 10µl of elute used 
in real-time 
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PCR PROCEDURE: 
DETECTION MIX 
COMPONENTS VOLUME 
Components  volume 
RT Probe PCR mastermix 8µl 
RT enzyme mix 2µl 
JEV Primer Probe Mix 2.5µl 
Internal control Primer Probe Mix 
[IC PP Mix 2.5µl 
Purified Viral RNA sample 10µl 
Total reaction volume 25µl 
 
 
Centrifuged PCR vials briefly before placing into thermal cycler. 
 
NEGATIVE CONTROL SETUP 
Included 10µl of nuclease free. 
 
POSITIVE CONTROL SETUP 
Included 10µl of Positive control. 
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TABLE: 4 AMPLIFICATION PROTOCOL 
 
 
 
 
 
 
 
45 cycles 
 
Step 
 
Time 
 
Temp 
Reverse 
transcriptase 
30sec 42° c 
Taq enzyme 
activation 
15sec 95° c 
Denaturation 20sec 95°c 
Annealing/Data 
collection 
20sec 56°c 
Extension 20sec 72°c 
 
         
 
         JEV = FAM channel Internal Control = JOE/HEX/VIC/Cy3 Channel 
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ELISA RESULTS 
                                  
 
 
 
                                             FIG: 6 ELISA KIT 
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FIG 7: ELISA INTERPRETATION 
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CALCULATION OF ISR VALUE 
NEGATIVE CONTROL 
 
ANTIGEN 
 
JERA 
 
NCA  
 
NO 1 
 
0.170 
 
0.50 
 
NO2 
 
0.101 
 
0.50 
 
TOTAL 
 
0.271 
 
0.100 
 
 
AVERAGES FOR JERA = 0.271/2 =0.135 
 
AVERAGE FOR NCA=0.100/2=0.50 
 
JERA/NCA RATIO=0.135/0.50=0.27 
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CALCULATION OF ISR VALUE 
POSITIVE CONTROL 
 
 
ANTIGEN 
 
JERA 
 
NCA  
 
NO 1 
 
0.772 
 
0.100 
 
NO2 
 
0.350 
 
01.00 
 
TOTAL 
 
 
1.222 
 
 
0.200 
 
 
AVERAGES FOR JERA = 1.222/2 =0661 
 
AVERAGE FOR NCA=0.200/2=0.100 
 
JERA/NCA RATIO=0.661/0.100=6.61 
 
. 
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PCR RESULTS 
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63 
 
 
 
 
 
 Amplification  plot of RT PCR genotyping of JEV. Cycle threshold for 1 
sample were detected as sample-1 belongs to JEV genotype – 3. 
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Interpretation 
 Sample 1-JEV genotype 3 identified in FAM channel 
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                                 RESULTS AND INTERPRETATION 
During the study period from June 2015-June 2016 a total of 100 CSF 
samples were collected and tested for JE IgM antibody at central service 
diagnostic laboratory, Departmentment of microbiology, Tertiary care hospital, 
Thanjavur medical college, Thanjavur. 
 
TABLE: 5 AGE WISE DISTRIBUTION 
 
AGE(years) 
 
NO.OF CASES 
 
PERCENTAGE (%) 
<20 yrs  42 
 
42% 
21-30 yrs  5 
 
5% 
31-40yrs  8 
 
8% 
41-50 yrs  12 
 
12% 
51-60 yrs  18 
 
18% 
61-70 yrs  9 
 
9% 
71 &ABOVE  6 
 
6% 
TOTAL  100 
 
100% 
 
Table 5 shows the age wise distribution of cases. A total of 100 CSF samples 
were tested for JE IgM. 
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               TABLE 6: GENDER DISTRIBUTION OF SUSPECTED CASES 
GENDER < 20 >20 Total Percentage 
MALE 4 50 54 72 % 
FEMALE 2 19 21 28 % 
 
Out of 100 samples 54 samples collected from male patients and 21 samples 
collected from female patients. 
In this study male population contributes 72%, female population contributes 
28%. 
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                                   FIG 8: GENDER DISTRIBUTION 
 
 
67%
33%
Gender Distribution
MALE FEMALE
7%
93%
Gender Distribution
< 20 >20
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                        TABLE 7: MALE AND FEMALE CHILD DISTRIBUTION 
GENDER <2 >2 Total 
MALE 
CHILD 11 4 15 
FEMALE 
CHILD 5 5 10 
 
 
 
                                  FIG 9: CHILD DISTRIBUTION 
 
   
0 2 4 6 8 10 12
<2
>2
<2 >2
FEMALE CHILD 5 5
MALE CHILD 11 4
Child Distribution
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                      TABLE 8:  JEV IGM POSITIVE CASES BY ELISA 
 
RESULT 
 
TOTAL CASES 
 
PERCENTAGE (%) 
 
POSITIVE 
 
1 
 
1% 
 
NEGATIVE 
 
99 
 
99% 
 
 
 
                     FIG: 10 JEV POSITIVE AND NEGATIVE PERCENTAGE 
 
 
 
 
1%
99%
JE POSITIVE CASES
Positive
Negative
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TABLE 9:  SEASONAL DISTRIBUTIONS 
MONTHS NO OF CASES PERCENTAGE 
JUNE 9 9 % 
JULY 17 17 % 
AUGUST 15 15 % 
SEPTEMBER 13 13 % 
OCTOBER 13 13 % 
NOVEMBER 11 11 % 
DECEMBER 8 8 % 
JANUARY 5 5 % 
FEBRUARY 5 5 % 
MARCH 4 4% 
Total 100 100 
 
In this study out of 100 samples maximum number of sampled were collected 
on July and lowest samples were collected from March.  
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FIG 11: SEASONAL DISSTRIBUTION 
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TABLE 10:  CLINICAL FEATURES STUDIES 
 
 
 In this study out of 100 patients, 71 patients came with fever, 12 
patients with head ache, 8 patient with seizure, 4 patients with vomiting, 
4patients with neck rigidity and 1patient with hemiparesis . 
 
 
 
 
 
Disease No of Cases Percentage 
Fever 71 71 % 
Headache 12 12 % 
Seizure 8 8 % 
Vomiting 4 4 % 
Neck    
Rigidity 4 4 % 
Hemiparesis  
Fever 1 1 % 
Total 100 100 
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            FIG 12: CLINICAL FEATURE DISTRIBUTION 
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            TABLE10: CLINICAL FEATURES WITH AGE 
Disease < 20         >20 
Fever 
Yes 
 
No 
33 
28 
 
5 
38 
30 
 
8 
Headache 
Yes 
 
No 
1 
1 
 
0 
11 
6 
 
5 
Seizure 
Yes 
 
No 
8 
7 
 
1 
0 
0 
 
0 
Vomiting 
Yes 
 
No 
0 
0 
 
0 
4 
2 
 
2 
Neck    Rigidity 
Yes 
 
No 
0 
0 
 
0 
4 
3 
 
1 
Hemiparesis  Fever 
Yes 
 
No 
0 
0 
 
0 
1 
1 
 
0 
Total 100  
 
In this study age is compared with clinical features 
Less than 20 age groups and more than 20 age groups shows fever the main 
clinical symptom. 
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TABLE 11: REAL TIME PCR  AND ELISA 
 
METHOD 
 
POSITIVE 
 
NEGATIVE 
  
 TOTAL 
ELISA 1 99 100 
Real-time PCR 1 99 100 
 
 
 Table11  shows that out of 100 samples,1 sample (1%) was positive for 
JEV RNA and 99 samples were negative (99%) for JEV RNA by Real- time 
PCR assay. Out of 100 samples, 1(1%) sample was positive both by ELISA and 
Real- time PCR assay. 
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DISCUSION 
The thriving supervision of patients suffering from illness depends upon 
the identification of the type of organisms that cause the diseases. Consequently 
data offered in this study could endow with information of immediate public 
health importance to physicians in Thanjavur Medical College hospital for the 
management of patients suffering from meningoencephalitis. Laboratory 
investigation of CSF or serum specimens in suspected cases of 
meningoencephalitis are important for prompt diagnosis and management of 
patients 
 
100 CSF samples collected from patients suspected meningoencephalitis 
processed for CSF biochemical analysis, cell count analysis, IgM capture 
ELISA for JEV and molecular characterization by RT-PCR for JEV ELISA 
positive sample 
 Greenlee et al1 explained about the CSF changes in the meningitis as 
well as in encephalitis that elevation of protein level in CSF correlates 
with this study. 
 
  Biochemical analysis shows increased protein levels in 7 samples. 
Sugar level was elevated in 2 samples.  
 
 
 Out of 100 samples 7 sample shows abnormal results which is 7%, 
among the 7 samples 5 samples shows increased protein levels and 
other two samples shows increased sugar level. 
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  Out of 7 samples 1 sample exhibit bacterial culture positive remaining 
6 shows negative, so there is definite correlation between the CSF 
sugar and protein elevation and bacterial culture positivity 
 Cell count analysis was observed. 
 6 samples shows abnormal results which accounts for 6%. 
 Kida S, et al4 .explains the CSF cell count analysis.  
 
In this study among the 6 samples which shown abnormal cell count, out 
of this 6 samples 
  2 to 3 neutrophils were observed in 2 samples. 
  4 to 5 lymphocytes  were noted in 4 samples. 
 Single neutrophil in the CSF sample is pathogenic. 
 In this study, age wise distribution exhibit most number of 
suspected cases from the age group of less than 20 which 
accounts for 43%.5% from the group of age 20 to 30,7% from 
the group of age 30 to 40,12% from the group of age 40 to 
50,18% from the group age 50 to 60,9%from the group of age 
60 to 70,6% from above 70.  
 Male female distribution exhibits the male dominance which is 
72% when compared to female which is 28%. 
 Fever is the most common presentation of suspected cases 
which accounts for 71%, headache accounts for 12% and seizure 
for 8%. 
 Seasonal distribution exhibit most number of suspected cases 
come from July then October and November. 
 Out of 100 suspected cases, positive from march month which is 
contrary to the previous statement. 
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 Negative samples may be due to other infections like bacterial, 
fungal, and other viral meningoencephalitis. 
 Diagana M11, Preux PM et al studied about the sero positivity of 
test IgM ELISA. 
 IgM capture ELISA was done for 100 CSF samples, out of 100 
samples 1 sample exhibit positive which accounts for 1%.  
 This sample is compared with cell count and sugar protein level 
of CSF, 
 9 lymphocytes were observed in this sample as well as raised 
protein level, sugar level observed in normal limits. 
 This explains about the infection of the central nervous system 
strongly associated with the elevated levels of protein and the 
cell count. 
 Gourie-Devi M, Ravi V et al18, explains the demographic 
profile as well as the seasonal distribution of cases shows the 
positive IgM  ELISA test with cytological profile. 
 CSF positive for JEV in ELISA sample is processed for RT- 
PCR, for genome identification as well as to access the 
reliability of the IgM capture ELISA  
 IgM positive sample shows positivity in PCR also, and the 
identified gene is E. 
 There are 5 genotypes have been identified till now, genotype 1 
and 3 were more common in India. 
 In this study genotype 3 is identified which is more commonly 
identified in India previously. 
 In our country like india, cost effective diagnostic method is 
necessary. 
 Standard test like PCR and cell culture methods can not be done 
for all suspected cases. 
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 Cell culture method is time consuming and costly for our setup. 
 PCR is costly, well trained staffs are needed to initiate the 
procedure. 
 So we are in need of cost effective diagnostic method and it 
should be very reliable when compared to the standard tests like 
PCR and cell culture. 
 In this study, 100 samples   are tested for IgM ELISA , out of 
100 samples one sample shows positive which is one 
percentage. 
 This positive sample was sent to the PCR study where they 
identified the E gene which is more specific for Japanese 
encephalitis. In my study results of IgM ELISA is concurrent 
with PCR.  
 In our setup, IgM ELISA can be used for the diagnosis of JEV in 
place of  PCR . 
 IgM ELISA along with biochemical analysis and cell count can 
be used in place of PCR for earlier diagnosis and management. 
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SUMMARY 
• The study was conducted at Thanjavur Medical College Hospital. 
Thanjavur over a period of June 2015 to June 2016. 
• The aim of the study is to determine the seroprevalence Japanese 
encephalitis virus in patients attending tertiary care hospital and 
molecular characterization for JEV.  
• CSF samples were collected from 100 suspected 
meningoencephalitis patients. 
• CSF is examined macroscopically for clarity and microscopically for 
pus cells, bacteria and yeast cell . 
• Then all the samples were analyzed for cell count and biochemical 
parameters.  
• Then samples were tested for IgM antibodies by capture ELISA 
method. Finally IgM positive samples were processed to identify the 
molecular characterization by RT-PCR method..  
• Real time PCR was done for 6 samples, including both one  positive 
and 5 negative by IgM ELISA for JEV.  
• Out of 6 samples, 1 sample shown positive by RT-PCR, which was 
already noted positive by ELISA. 
• Prevalence of JEV in thanjavur 1%. 
• High prevalence was seen among children in the age group 5-10 
years. 
• Real –time PCR for JEV was positive for one sample (100%) which 
is shown positive by Elisa. 
•  IgM antibody measurement in CSF sample by ELISA along with 
cytological and biochemical analysis is as good as RT-PCR in the 
early diagnosis 
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                                                      CONCLUSION 
 
This study estimates the seroprevalence of Japanese encephalitis in a 
tertiary care hospital Thanjavur. The seroprevalence of Japanese encephalitis 
was estimated as 1% .The prevalence of JEV was high among children in the 
age group of 5 to 15.In this study the observed prevalence of 1% is coincided 
with the actual prevalence in thanjavur.This study estimates the magnitude and 
dynamics of disease transmission .Isolation of virus by cell culture method and 
Real –time PCR are the standard diagnostic methods. RT-PCR estimates the 
viral load and can identify the genotyping, because both viral load and 
genotyping plays an important role in management strategy. Moreover knowing 
about the genotypes in the community helps in the development of future 
vaccine. Further studies of genotype distribution will helps in the development, 
adaptation and prevention strategies RT-PCR and isolation is very difficult 
because of its cost. At this fact IgM antibody measurement in CSF sample by 
ELISA along with cytological and biochemical analysis is as good as RT-PCR 
in the early diagnosis. Early diagnosis prevents the disease progression and 
further complications.  
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LIMITATIONS 
 
1. Faulty biochemical reports due to 
 Improper procedure of lumbar puncture  
 Antibiotic treatment prior to lumbar puncture. 
 Delay in transport of specimen  
 Improper storage. 
 Autolytic enzymes in CSF. 
 Fastidious nature of pathogen. 
 
 
 
2. Sample size is small 
 
3. One year comparative study 
 
 
 
 
 
 
 
 
 
  
 PROFORMA 
 
     Name:                     Serial No:                                   
     Age:       Lab No: 
     Sex:       Op/Ip No:    
          
     Address:        Date of Sample Collection:                        
     Occupation:        Specimen: 
     Income:                              Test:  
 
    Chief Complaints: 
1. Fever 
2. Altered Sensorium 
3. Neck Stiffness 
4. Vomiting 
5. Convulsions 
 
Past History: 
 
Clinical Diagnosis: 
 
                                  
 
 
 
 
 
 
  
 
 
  
 
CONSENT FORM 
 
 
I                                                 hereby give consent to participate in the study 
conducted by Dr.R.GOPINATHAN, post graduate in the department of 
microbiology, thanjavur medical college thanjavur-613004 and to use my 
personel clinical data and result of investigation for the purpose of analysis and 
to study the nature of disease .I also give consent for further investigations 
 
 
 
 
Place:                                                               Signature of participant 
 
Date: 
 
 
 
 
 
 
 
 
 INFORMATION SHEET 
 
• We are conducting cross sectional and comparative study on  
 
• To   study  the evaluation of  conventional culture  methods  and  
serodiagnostic  methods    for    clinically    diagnosed   as  
meningoencephalitis    in   patients admitted in Thanjavur 
medical college hospital  with   special reference to  Japanese 
encephalitis   in the department of  microbiology thanjavur medical 
college Thanjavur. 
 
• At the time of announcing the results and suggestions ,name and the 
identy of the patients will be confidential. 
 
• Taking part in the study is voluntary . You are free to decide 
wheather to participate in this study or to withdraw at any one time 
;your decision will not result in any loss of benefits to which you are 
otherwise entitiled. 
 
• The results of the study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which 
may aid in the management or treatment. 
 
 
Signature of Investigator                            Signature  of  Participant 
 
Date 
 
 
 
 
 S.NO 
BIOCHEMICAL 
ANALYSIS 
Sugar/Protein 
CELL 
COUNT CULTURE RESULTS JE ELISA PCR 
1 100 / 50 Nil No Growth Negative Negative 
2 48 / 40 Nil No Growth Negative Negative 
3 55 / 50 Nil No Growth Negative Negative 
4 20 / 40 Nil No Growth Negative Negative 
5 49 / 50 Nil No Growth Negative Negative 
6 83 /40 Nil No Growth Negative Negative 
7 71 / 50 Nil No Growth Negative Negative 
8 112 / 70 Nil No Growth Negative Negative 
9 63 / 40 Nil No Growth Negative Negative 
10 64 / 50 Nil No Growth Negative Negative 
       11 30 / 50 Nil No Growth Negative Negative 
12 40 / 70 Nil No Growth Negative Negative 
13 50 / 60 Nil No Growth Negative Negative 
14 40 / 60 Nil No Growth Negative Negative 
15 46 / 63 Nil No Growth Negative Negative 
16 52 / 476 N1/L3 No Growth Negative Negative 
17 42 / 472 N3/L9 No Growth Negative Negative 
18 51 / 63 Nil No Growth Negative Negative 
19 47 / 59 Nil No Growth Negative Negative 
20 36 / 58 Nil No Growth Negative Negative 
21 49 / 62 Nil No Growth Negative Negative 
22 39/48 Nil No Growth Negative Negative 
23 52/61 Nil No Growth Negative Negative 
24 43/59 Nil No Growth Negative Negative 
25 36/47 Nil No Growth Negative Negative 
26 51/597 L3 No Growth Negative Negative 
27 55/489 L5 No Growth Negative Negative 
28 42/61 Nil No Growth Negative Negative 
29 49/71 Nil No Growth Negative Negative 
30 39/62 Nil No Growth Negative Negative 
31 43/62 Nil No Growth Negative Negative 
32 44/67 Nil No Growth Negative Negative 
33 48/71 Nil No Growth Negative Negative 
34 55/65 Nil No Growth Negative Negative 
35 52/67 Nil No Growth Negative Negative 
36 41/59 Nil No Growth Negative Negative 
MASTER CHART 
 S.NO 
BIOCHEMICAL 
ANALYSIS 
Sugar/Protein 
CELL 
COUNT CULTURE RESULTS JE ELISA PCR 
37 44/64 Nil No Growth Negative Negative 
38 45/72 Nil No Growth Negative Negative 
39 51/465 N1/L5 No Growth Negative Negative 
40 45/72 Nil No Growth Negative Negative 
41 46/61 Nil No Growth Negative Negative 
42 49/69 Nil No Growth Negative Negative 
43 57/72 Nil No Growth Negative Negative 
44 54/68 Nil No Growth Negative Negative 
45 55/65 Nil No Growth Negative Negative 
46 56/62 Nil No Growth Negative Negative 
47 35/60 Nil No Growth Negative Negative 
48 51/70 Nil No Growth Negative Negative 
49 61/71 Nil No Growth Negative Negative 
50 58/72 Nil No Growth Negative Negative 
51 42/63 Nil No Growth Negative Negative 
52 44/75 Nil No Growth Negative Negative 
53 38/60 Nil No Growth Negative Negative 
54 42/61 Nil No Growth Negative Negative 
55 55/71 Nil No Growth Negative Negative 
56 42/71 Nil No Growth Negative Negative 
57 52/63 Nil No Growth Negative Negative 
58 32/51 Nil No Growth Negative Negative 
59 51/62 Nil No Growth Negative Negative 
60 42/52 Nil No Growth Negative Negative 
61 61/73 Nil No Growth Negative Negative 
62 57/65 Nil No Growth Negative Negative 
63 49/58 Nil No Growth Negative Negative 
64 60/70 Nil No Growth Negative Negative 
65 51/59 Nil No Growth Negative Negative 
66 61/75 Nil No Growth Negative Negative 
67 55/78 Nil No Growth Negative Negative 
68 52/71 Nil No Growth Negative Negative 
69 62/80 Nil No Growth Negative Negative 
70 55/59 Nil No Growth Negative Negative 
71 62/71 Nil No Growth Negative Negative 
72 36/71 Nil No Growth Negative Negative 
73 45/71 Nil No Growth Negative Negative 
74 55/65 Nil No Growth Negative Negative 
75 42/59 Nil No Growth Negative Negative 
  
 
S.NO 
BIOCHEMICAL 
ANALYSIS 
Sugar/Protein 
CELL 
COUNT CULTURE RESULTS JE ELISA PCR 
76 55/76 Nil No Growth Negative Negative 
77 49/76 Nil No Growth Negative Negative 
78 51/73 Nil No Growth Negative Negative 
79 50/60 Nil No Growth Negative Negative 
80 55/72 Nil No Growth Negative Negative 
81 39/58 Nil No Growth Negative Negative 
82 59/78 Nil No Growth Negative Negative 
83 61/82 Nil No Growth Negative Negative 
84 
47/49 Nil No Growth Negative Negative 
85 51/72 Nil No Growth Negative Negative 
86 52/71 Nil No Growth Negative Negative 
87 44/52 Nil No Growth Negative Negative 
88 52/455 N1/L3 klebsella pneumoniae Negative Negative 
89 36/62 Nil No Growth Negative Negative 
90 
42/49 Nil No Growth Negative Negative 
91 32/54 Nil No Growth Negative Negative 
92 54/68 Nil No Growth Negative Negative 
93 57/81 Nil No Growth Negative Negative 
94 43/61 Nil No Growth Negative Negative 
95 51/75 Nil No Growth Negative Negative 
96 53/74 Nil No Growth Negative Negative 
97 59/78 Nil No Growth Negative Negative 
98 51/76 Nil No Growth Negative Negative 
99 55/423 N2/L5 No Growth Positive positive 
100 
45/75 Nil No Growth Negative Negative 
 
     
 
     
